InvestorWire NewsRoom


InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Ability to Speed Up COVID-19 Testing Using PCR Equipment
February 11, 2021

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Ability to Speed Up COVID-19 Testing Using PCR Equipment

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has partnered with a German diagnostics firm to become a leader in commercializing breakthrough tech in rapid, definitive testing for COVID-19 in strategic and convenient point-of-care (“POC”) settings. A recent article noted that, using standard polymerase chain reaction (“PCR”) equipment, XPhyto has the ability to significantly speed up testing for COVID-19. The equipment is commonly found in most analytical laboratories as well as hospitals and a range of POC settings. The announcement was based on the successful trial validation results of XPhyto’s proprietary rapid PCR test kit, developed in collaboration with Stuttgard-based 3a-Diagnostics GmbH. The company plans on initially applying for regulatory approval in Germany while also preparing for a commercial launch of its product early this year. The article reported that faster definitive diagnostic processes were especially urgent as the go-to rapid antigen testing has fallen out of favor; the article also called PCR the gold standard for coronavirus testing because of its reliability for generating accurate results. “XPhyto’s announcement attests to the completion of successful validation trials, which demonstrated diagnostic-level sensitivity and specificity for the test kit,” the article stated. “However, it is not the high degree of accuracy that really sets the test apart; instead, it is the ability to shorten testing turnaround times from at least a few hours to as little as 25 minutes. . . .XPhyto’s kit only requires a single PCR cycle which is complete in 20 minutes, while most PCR test systems require at least an hour — and sometimes several — to complete a mult-step viral RNA amplification process. XPhyto’s test kit also requires significantly less non-PCR laboratory processing time, including labour. Furthermore, it employs reagents that are readily available.”

For more information, visit

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).